Regulators in the UK and US are the first to approve GSK's Exdensur, a long-acting, twice-yearly IL-5 inhibitor for severe asthma that has been billed as a major new product for the drugmaker. In the ...
With a fresh endorsement from the FDA, the last of five major drug approvals has fallen into place for GSK in 2025. Tuesday, the U.S. regulator greenlit GSK’s depemokimab, an ultra-long-acting ...
The FDA has approved GSK’s Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in patients ages 12 and older. The approval is based on data ...
The U.S. health regulator has approved GSK's add-on drug to treat severe asthma, the drugmaker said on Tuesday, paving the way for a less frequently dosed treatment option for patients to enter the ...
GlaxoSmithKline announced that the US Food and Drug Administration has approved its twice-annual asthma therapy Exdensur, offering a new option for patients aged 12 and older with severe eosinophilic ...
Millennial Skin on MSN
Lavender does more than smell good — the science behind its powerful effects on sleep, skin, and stress
Lavender has long been associated with calm, cleanliness, and comfort, but its reputation is not built on fragrance alone.
Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is GSK's depemokimab, a long-acting anti-IL-5 antibody for severe asthma and an ...
Lindsay Curtis is a health & medical writer in South Florida. She worked as a communications professional for health nonprofits and the University of Toronto’s Faculty of Medicine and Faculty of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback